In Vivo Cancer Dual-Targeting and Dual-Modality Imaging with Functionalized Quantum Dots
Semiconductor quantum dots (QDs), after surface modification to provide water solubility and biocompatibility, have a promising future in biomedical applications. In this study, a dual receptor-targeting dual-modality PET/near-infrared fluorescence (NIRF) probe was developed for accurate assessment...
Saved in:
Published in | Journal of Nuclear Medicine Vol. 56; no. 8; pp. 1278 - 1284 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Society of Nuclear Medicine
01.08.2015
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Semiconductor quantum dots (QDs), after surface modification to provide water solubility and biocompatibility, have a promising future in biomedical applications. In this study, a dual receptor-targeting dual-modality PET/near-infrared fluorescence (NIRF) probe was developed for accurate assessment of the pharmacokinetics and tumor-targeting efficacy of QDs.
QDs were modified by β-Glu-RGD-BBN (RGD is arginine-glycine-aspartate acid, and BBN is bombesin) peptides and then labeled with (18)F via the 4-nitrophenyl-2-(18)F-fluoropropionate prosthetic group. Cytotoxicity and cell-binding assay of QD-RGD-BBN were performed with PC-3 cells. In vivo dual-modality PET/NIRF imaging of prostate tumor-bearing mice was investigated using QD-RGD-BBN and 2-(18)F-fluoropropionyl-QD-RGD-BBN ((18)F-FP-QD-RGD-BBN). An in vivo biodistribution study of (18)F-FP-QD-RGD-BBN was performed on normal mice.
QD-RGD-BBN exhibited strong red luminescence (600-800 nm) with the same maximum fluorescence wavelength (705 nm) as QD705 and slightly lower toxicity than that of QD705 in PC-3 cells at concentrations of greater than 30 μg/mL. Uptake of QD-RGD-BBN in PC-3 cells showed no significant decrease in the presence of an excess amount of dimer arginine-glycine-aspartate acid (RGD2) or bombesin(7-14) (BBN) peptide but was blocked significantly in the presence of an excess amount of NH2-RGD-BBN. Dual-function PET/NIRF imaging is able to accurately assess the biodistribution and tumor-targeting efficacy of the (18)F-labeled functionalized QDs.
The functionalized QD probe has great potential as a universal dual-targeting probe for detecting tumors in living subjects, opening up a new strategy for the development of multitargeting multimodality (18)F-labeled QD probes with improved tumor-targeting efficacy. |
---|---|
AbstractList | Semiconductor quantum dots (QDs), after surface modification to provide water solubility and biocompatibility, have a promising future in biomedical applications. In this study, a dual receptor-targeting dual-modality PET/near-infrared fluorescence (NIRF) probe was developed for accurate assessment of the pharmacokinetics and tumor-targeting efficacy of QDs.
QDs were modified by β-Glu-RGD-BBN (RGD is arginine-glycine-aspartate acid, and BBN is bombesin) peptides and then labeled with (18)F via the 4-nitrophenyl-2-(18)F-fluoropropionate prosthetic group. Cytotoxicity and cell-binding assay of QD-RGD-BBN were performed with PC-3 cells. In vivo dual-modality PET/NIRF imaging of prostate tumor-bearing mice was investigated using QD-RGD-BBN and 2-(18)F-fluoropropionyl-QD-RGD-BBN ((18)F-FP-QD-RGD-BBN). An in vivo biodistribution study of (18)F-FP-QD-RGD-BBN was performed on normal mice.
QD-RGD-BBN exhibited strong red luminescence (600-800 nm) with the same maximum fluorescence wavelength (705 nm) as QD705 and slightly lower toxicity than that of QD705 in PC-3 cells at concentrations of greater than 30 μg/mL. Uptake of QD-RGD-BBN in PC-3 cells showed no significant decrease in the presence of an excess amount of dimer arginine-glycine-aspartate acid (RGD2) or bombesin(7-14) (BBN) peptide but was blocked significantly in the presence of an excess amount of NH2-RGD-BBN. Dual-function PET/NIRF imaging is able to accurately assess the biodistribution and tumor-targeting efficacy of the (18)F-labeled functionalized QDs.
The functionalized QD probe has great potential as a universal dual-targeting probe for detecting tumors in living subjects, opening up a new strategy for the development of multitargeting multimodality (18)F-labeled QD probes with improved tumor-targeting efficacy. Semiconductor quantum dots (QDs), after surface modification to provide water solubility and biocompatibility, have a promising future in biomedical applications. In this study, a dual receptor-targeting dual-modality PET/near-infrared fluorescence (NIRF) probe was developed for accurate assessment of the pharmacokinetics and tumor-targeting efficacy of QDs. QDs were modified by -Glu-RGD-BBN (RGD is arginine-glycine-aspartate acid, and BBN is bombesin) peptides and then labeled with ...via the 4-nitrophenyl-2-...-fluoropropionate prosthetic group. Cytotoxicity and cell-binding assay of QD-RGD-BBN were performed with PC-3 cells. In vivo dual-modality PET/NIRF imaging of prostate tumor-bearing mice was investigated using QD-RGD-BBN and 2-...-fluoropropionyl-QD-RGD-BBN (...-FP-QD-RGD-BBN). An in vivo biodistribution study of ...-FP-QD-RGD-BBN was performed on normal mice. QD-RGD-BBN exhibited strong red luminescence (600-800 nm) with the same maximum fluorescence wavelength (705 nm) as QD705 and slightly lower toxicity than that of QD705 in PC-3 cells at concentrations of greater than 30 ...g/mL. Uptake of QD-RGD-BBN in PC-3 cells showed no significant decrease in the presence of an excess amount of dimer arginine-glycine-aspartate acid (RGD...) or bombesin(7-14) (BBN) peptide but was blocked significantly in the presence of an excess amount of NH...-RGD-BBN. Dual-function PET/NIRF imaging is able to accurately assess the biodistribution and tumor-targeting efficacy of the ...-labeled functionalized QDs. The functionalized QD probe has great potential as a universal dual-targeting probe for detecting tumors in living subjects, opening up a new strategy for the development of multitargeting multimodality ...-labeled QD probes with improved tumor-targeting efficacy. (ProQuest: ... denotes formulae/symbols omitted.) Semiconductor quantum dots (QDs), after surface modification to provide water solubility and biocompatibility, have a promising future in biomedical applications. In this study, a dual receptor-targeting dual-modality PET/near-infrared fluorescence (NIRF) probe was developed for accurate assessment of the pharmacokinetics and tumor-targeting efficacy of QDs. QDs were modified by β-Glu-RGD-BBN (RGD is arginine-glycine-aspartate acid, and BBN is bombesin) peptides and then labeled with ...via the 4-nitrophenyl-2-...-fluoropropionate prosthetic group. Cytotoxicity and cell-binding assay of QD-RGD-BBN were performed with PC-3 cells. In vivo dual-modality PET/NIRF imaging of prostate tumor-bearing mice was investigated using QD-RGD-BBN and 2-...-fluoropropionyl-QD-RGD-BBN (...-FP-QD-RGD-BBN). An in vivo biodistribution study of ...-FP-QD-RGD-BBN was performed on normal mice. QD-RGD-BBN exhibited strong red luminescence (600-800 nm) with the same maximum fluorescence wavelength (705 nm) as QD705 and slightly lower toxicity than that of QD705 in PC-3 cells at concentrations of greater than 30 ...g/mL. Uptake of QD-RGD-BBN in PC-3 cells showed no significant decrease in the presence of an excess amount of dimer arginine-glycine-aspartate acid (RGD...) or bombesin(7-14) (BBN) peptide but was blocked significantly in the presence of an excess amount of NH...-RGD-BBN. Dual-function PET/NIRF imaging is able to accurately assess the biodistribution and tumor-targeting efficacy of the ...-labeled functionalized QDs. The functionalized QD probe has great potential as a universal dual-targeting probe for detecting tumors in living subjects, opening up a new strategy for the development of multitargeting multimodality ...-labeled QD probes with improved tumor-targeting efficacy. (ProQuest: ... denotes formulae/symbols omitted.) |
Author | Tang, Ganghua Nie, Dahong Tang, Xiaolan Wang, Hongliang Hu, Kongzhen Huang, Tingting Liang, Xiang Yao, Shaobo |
Author_xml | – sequence: 1 givenname: Kongzhen surname: Hu fullname: Hu, Kongzhen – sequence: 2 givenname: Hongliang surname: Wang fullname: Wang, Hongliang – sequence: 3 givenname: Ganghua surname: Tang fullname: Tang, Ganghua – sequence: 4 givenname: Tingting surname: Huang fullname: Huang, Tingting – sequence: 5 givenname: Xiaolan surname: Tang fullname: Tang, Xiaolan – sequence: 6 givenname: Xiang surname: Liang fullname: Liang, Xiang – sequence: 7 givenname: Shaobo surname: Yao fullname: Yao, Shaobo – sequence: 8 givenname: Dahong surname: Nie fullname: Nie, Dahong |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26112023$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kUtLw0AUhQepaK3-ADcScOMmdWaSeS2ltVqoiFDFXZikkzolmdF5KPrrTUl14cLVhXu-c7mccwQGxhoFwCmCYywou9yY2KrVGCEyRoRzlu2BIUZEpJTi5wEYQkRRSggkh-DI-w2EkHLOD8AhpghhiLMheJ6b5Em_22QiTaVcMo2ySZfSrVXQZp1Is-pXd3YlGx0-k3kr11vlQ4eXZBZNFbQ1nfSlVslDlCbENpna4I_Bfi0br052cwQeZ9fLyW26uL-ZT64WaZVDElLByiwToq5yXisp8hwzmYs6UyXHSHBGJSawhLUUrKJYYFpDxiijZYlETZDIRuCiv_vq7FtUPhSt9pVqGmmUjb5AjEOCCcqyDj3_g25sdN3zWwpiBkneZTgCZzsqll26xavTrXSfxU9mHYB6oHLWe6fqXwTBYttL0fdSdL0UfS-dh_3xVDrIbXTBSd384_wGvKaR8Q |
CODEN | JNMEAQ |
CitedBy_id | crossref_primary_10_1007_s40820_018_0216_2 crossref_primary_10_1039_C7NR00298J crossref_primary_10_1002_chem_202001402 crossref_primary_10_1021_acs_bioconjchem_1c00503 crossref_primary_10_2174_1381612826666200721001500 crossref_primary_10_1038_srep21959 crossref_primary_10_3390_biomedicines8090307 crossref_primary_10_3390_molecules29071537 crossref_primary_10_1016_j_fct_2017_07_006 crossref_primary_10_1016_j_tibtech_2017_08_006 crossref_primary_10_1002_cplu_202100171 crossref_primary_10_38124_ijisrt_IJISRT24NOV1416 crossref_primary_10_1007_s40336_018_0283_x crossref_primary_10_1002_psc_3224 crossref_primary_10_1016_j_jconrel_2024_03_015 crossref_primary_10_1002_pep2_24205 crossref_primary_10_1002_advs_201600279 crossref_primary_10_3390_ijms24043455 crossref_primary_10_1515_ejnm_2016_0011 crossref_primary_10_3390_molecules28104122 crossref_primary_10_3390_ijms232213735 crossref_primary_10_1002_jbm_a_36862 crossref_primary_10_1016_j_jlumin_2019_01_011 crossref_primary_10_1016_j_actbio_2018_05_049 crossref_primary_10_1016_j_addr_2016_08_001 crossref_primary_10_1021_acs_chemrev_6b00290 crossref_primary_10_1021_acs_jmedchem_6b00025 crossref_primary_10_1142_S1793545823300082 crossref_primary_10_33483_jfpau_1323924 |
Cites_doi | 10.1016/j.nucmedbio.2013.06.006 10.1128/AEM.67.10.4458-4463.2001 10.2174/187152006778226530 10.2217/17435889.3.1.83 10.1002/mc.10117 10.2967/jnumed.107.048009 10.1021/nl902659g 10.1007/s10967-013-2736-z 10.1007/s00726-010-0762-5 10.1021/nl052405t 10.1021/la303957y 10.2967/jnumed.107.043216 10.1289/ehp.10290 10.1016/j.biomaterials.2010.10.022 10.1158/0008-5472.CAN-06-1185 10.1038/nbt994 10.1289/ehp.8284 10.1126/science.1069040 10.1038/nbt920 10.1021/nl025673p 10.1016/j.nucmedbio.2011.10.009 10.1021/jm801285t 10.1073/pnas.152463399 |
ContentType | Journal Article |
Copyright | 2015 by the Society of Nuclear Medicine and Molecular Imaging, Inc. Copyright Society of Nuclear Medicine Aug 1, 2015 |
Copyright_xml | – notice: 2015 by the Society of Nuclear Medicine and Molecular Imaging, Inc. – notice: Copyright Society of Nuclear Medicine Aug 1, 2015 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 4T- 8FD FR3 K9. M7Z NAPCQ P64 7QO |
DOI | 10.2967/jnumed.115.158873 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Docstoc Technology Research Database Engineering Research Database ProQuest Health & Medical Complete (Alumni) Biochemistry Abstracts 1 Nursing & Allied Health Premium Biotechnology and BioEngineering Abstracts Biotechnology Research Abstracts |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Nursing & Allied Health Premium Technology Research Database Docstoc Biochemistry Abstracts 1 ProQuest Health & Medical Complete (Alumni) Engineering Research Database Biotechnology and BioEngineering Abstracts Biotechnology Research Abstracts |
DatabaseTitleList | MEDLINE Engineering Research Database Nursing & Allied Health Premium |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2159-662X 1535-5667 |
EndPage | 1284 |
ExternalDocumentID | 3773075571 26112023 10_2967_jnumed_115_158873 |
Genre | Research Support, Non-U.S. Gov't Journal Article Feature |
GroupedDBID | 123 18M 41~ 5VS 96U AAYXX ACGFO AEGXH AIAGR ALMA_UNASSIGNED_HOLDINGS CITATION GX1 N9A RHI TSM U5U W8F --- -~X .55 .GJ 29L 2WC 3O- 53G 5RE 7RV 7X7 88E 88I 8AF 8AO 8FE 8FG 8FH 8FI 8FJ 8R4 8R5 8WZ A6W ABEFU ABSQV ABUWG ACGOD ACIWK ACPRK ADDZX ADMOG AENEX AFFNX AFKRA AFOSN AFRAH AHMBA AI. ALIPV ARAPS AZQEC BBNVY BENPR BGLVJ BHPHI BKEYQ BPHCQ BVXVI CCPQU CGR CS3 CUY CVF DIK DU5 DWQXO E3Z EBD EBS ECM EIF EJD EMOBN EX3 F5P F9R FYUFA GNUQQ H13 HCIFZ HMCUK I-F IL9 INIJC J5H KQ8 L7B LK8 M1P M2P M2Q M7P N4W NAPCQ NPM OK1 P2P P62 PHGZT PQQKQ PROAC PSQYO Q2X R0Z RNS RWL S0X SJN SV3 TAE TR2 TUS UKHRP VH1 WH7 WOQ WOW X7M YHG YQJ ZGI ZXP 4T- 8FD FR3 K9. M7Z P64 7QO |
ID | FETCH-LOGICAL-c405t-97b3399fc48fea94427a49f3eb8219876a250b0fa97c62926f077676bb19f5193 |
ISSN | 0161-5505 |
IngestDate | Fri Jul 11 15:23:23 EDT 2025 Mon Jun 30 10:37:02 EDT 2025 Thu Apr 03 07:08:26 EDT 2025 Tue Jul 01 01:45:13 EDT 2025 Thu Apr 24 23:12:23 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 8 |
Keywords | quantum dots integrin αvβ3 GRPR fluorescence PET |
Language | English |
License | 2015 by the Society of Nuclear Medicine and Molecular Imaging, Inc. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c405t-97b3399fc48fea94427a49f3eb8219876a250b0fa97c62926f077676bb19f5193 |
Notes | SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | http://jnm.snmjournals.org/content/56/8/1278.full.pdf |
PMID | 26112023 |
PQID | 1702705487 |
PQPubID | 40808 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_1780525133 proquest_journals_1702705487 pubmed_primary_26112023 crossref_primary_10_2967_jnumed_115_158873 crossref_citationtrail_10_2967_jnumed_115_158873 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2015-08-00 2015-Aug 20150801 |
PublicationDateYYYYMMDD | 2015-08-01 |
PublicationDate_xml | – month: 08 year: 2015 text: 2015-08-00 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: New York |
PublicationTitle | Journal of Nuclear Medicine |
PublicationTitleAlternate | J Nucl Med |
PublicationYear | 2015 |
Publisher | Society of Nuclear Medicine |
Publisher_xml | – name: Society of Nuclear Medicine |
References | 2021051712075857000_56.8.1278.10 2021051712075857000_56.8.1278.9 2021051712075857000_56.8.1278.11 2021051712075857000_56.8.1278.12 2021051712075857000_56.8.1278.5 2021051712075857000_56.8.1278.8 2021051712075857000_56.8.1278.2 2021051712075857000_56.8.1278.1 2021051712075857000_56.8.1278.4 2021051712075857000_56.8.1278.3 Tang (2021051712075857000_56.8.1278.16) 2012; 53 Tang (2021051712075857000_56.8.1278.7) 2011; 34 2021051712075857000_56.8.1278.18 2021051712075857000_56.8.1278.19 2021051712075857000_56.8.1278.14 2021051712075857000_56.8.1278.15 2021051712075857000_56.8.1278.17 2021051712075857000_56.8.1278.21 2021051712075857000_56.8.1278.22 2021051712075857000_56.8.1278.23 2021051712075857000_56.8.1278.24 2021051712075857000_56.8.1278.20 Tang (2021051712075857000_56.8.1278.6) 2012; 30 Zhang (2021051712075857000_56.8.1278.13) 2006; 47 2021051712075857000_56.8.1278.25 2021051712075857000_56.8.1278.26 2021051712075857000_56.8.1278.27 2021051712075857000_56.8.1278.28 |
References_xml | – ident: 2021051712075857000_56.8.1278.18 doi: 10.1016/j.nucmedbio.2013.06.006 – ident: 2021051712075857000_56.8.1278.26 doi: 10.1128/AEM.67.10.4458-4463.2001 – ident: 2021051712075857000_56.8.1278.9 doi: 10.2174/187152006778226530 – volume: 30 start-page: 568 year: 2012 ident: 2021051712075857000_56.8.1278.6 article-title: In situ visual imaging and in vivo distribution of head and neck squamous cell carcinoma in mice by near-infrared fluorescent quantum dots epidermal growth factor receptor monoclonal antibody probe publication-title: Hua Xi Kou Qiang Yi Xue Za Zhi. – ident: 2021051712075857000_56.8.1278.1 doi: 10.2217/17435889.3.1.83 – ident: 2021051712075857000_56.8.1278.11 doi: 10.1002/mc.10117 – ident: 2021051712075857000_56.8.1278.14 doi: 10.2967/jnumed.107.048009 – ident: 2021051712075857000_56.8.1278.25 doi: 10.1021/nl902659g – ident: 2021051712075857000_56.8.1278.19 doi: 10.1007/s10967-013-2736-z – ident: 2021051712075857000_56.8.1278.15 doi: 10.1007/s00726-010-0762-5 – ident: 2021051712075857000_56.8.1278.2 doi: 10.1021/nl052405t – ident: 2021051712075857000_56.8.1278.23 doi: 10.1021/la303957y – ident: 2021051712075857000_56.8.1278.8 doi: 10.2967/jnumed.107.043216 – volume: 34 start-page: 765 year: 2011 ident: 2021051712075857000_56.8.1278.7 article-title: Process of muti-targeted molecular imaging publication-title: Nucl Technol. – ident: 2021051712075857000_56.8.1278.22 doi: 10.1289/ehp.10290 – ident: 2021051712075857000_56.8.1278.24 doi: 10.1016/j.biomaterials.2010.10.022 – ident: 2021051712075857000_56.8.1278.3 doi: 10.1158/0008-5472.CAN-06-1185 – ident: 2021051712075857000_56.8.1278.5 doi: 10.1038/nbt994 – volume: 53 start-page: 1699 year: 2012 ident: 2021051712075857000_56.8.1278.16 article-title: Radiosynthesis and preliminary evaluation of 18F-FB-PEG-BBN-beta-Glu-RGD-QD as a new targeted dual-receptor dual-modality probe for tumor imaging [abstract] publication-title: J Nucl Med. – ident: 2021051712075857000_56.8.1278.28 doi: 10.1289/ehp.8284 – ident: 2021051712075857000_56.8.1278.10 doi: 10.1126/science.1069040 – ident: 2021051712075857000_56.8.1278.4 doi: 10.1038/nbt920 – ident: 2021051712075857000_56.8.1278.20 doi: 10.1021/nl025673p – ident: 2021051712075857000_56.8.1278.12 doi: 10.1016/j.nucmedbio.2011.10.009 – ident: 2021051712075857000_56.8.1278.17 – ident: 2021051712075857000_56.8.1278.27 doi: 10.1021/jm801285t – volume: 47 start-page: 492 year: 2006 ident: 2021051712075857000_56.8.1278.13 article-title: 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer publication-title: J Nucl Med. – ident: 2021051712075857000_56.8.1278.21 doi: 10.1073/pnas.152463399 |
SSID | ssj0006888 ssj0062072 |
Score | 2.3471563 |
Snippet | Semiconductor quantum dots (QDs), after surface modification to provide water solubility and biocompatibility, have a promising future in biomedical... |
SourceID | proquest pubmed crossref |
SourceType | Aggregation Database Index Database Enrichment Source |
StartPage | 1278 |
SubjectTerms | Animals Biocompatible Materials - chemistry Bombesin - pharmacokinetics Cancer Cells Copper Radioisotopes Cytotoxicity Female Fluorescence Male Mice Mice, Inbred BALB C Neoplasm Transplantation Neoplasms - diagnostic imaging Nitrophenols - chemistry Oligopeptides - chemistry Peptides - chemistry Positron-Emission Tomography Prostatic Neoplasms - diagnostic imaging Quantum Dots Receptors, Bombesin - metabolism Rodents Semiconductors Spectrometry, Fluorescence Tissue Distribution Tumors |
Title | In Vivo Cancer Dual-Targeting and Dual-Modality Imaging with Functionalized Quantum Dots |
URI | https://www.ncbi.nlm.nih.gov/pubmed/26112023 https://www.proquest.com/docview/1702705487 https://www.proquest.com/docview/1780525133 |
Volume | 56 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELdgSIgXND5XNiYj8USVkTixnTyisa6FdWhSCn2LnC821CVoNHvoX78720lavjR4SVsnuVS-X-7LvjtCXnt-UOZhxp0sKDi2MAsc5frKkYLLCDWMUJgoPD0V41nwYc7n_V5VnV2yTA-y1W_zSv6HqzAGfMUs2X_gbEcUBuA78BeOwGE43orHk2r4-eK6Hh4i666G7xu1cGK9tbtNPdRD0zo31vbk0vQk0sHXEWg0Ewi8WIHVedbAHDeXYFGb2k6txdrnji3Mpo8MG010a_K60BP4iGsRhXGjpUddfV2d94lmX2xgelxj4rCyClPHDMyJY_g8b1RPxY7HuMe_VbA2PuHxbndcF7IUnoN-0LrMNcXELbbCNQHqMdPRxyrj9ufPgp5FApeav1VALAexzw88DuLS77Vau5J_-ikZzU5OkvhoHt8l9xh4E9jo4uNZX1RehLo9afdHzeI3PuLtLw_YNF_-4JNo2yTeJg8te-g7g5BH5E5RPSb3p5ZFT8h8UlEECjVAoZtAoQAUugEUaoFCESh0EyjUAoUiUJ6S2egoPhw7tqUGvIsuXzqRTH0wScssCMtCRUHApAqi0i_SkGH4SSgwiVO3VJHMBIuYKHW5J5GmXlSisf-MbFV1VewQmhdK5j5QdV2gJmUqPaBShmWuOON5PiBuO1NJZuvNY9uTRQJ-J05uYiYXfFCemMkdkDfdLd9NsZW_XbzXTn9i38kfiSddJl30wgfkVXcaJCYug6mqqBu8Btt4YF-jAXlu2NY9jQnwP8CMfXGLu3fJgx7ve2RredUUL8FCXab7Gl8300OP-w |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=In+Vivo+Cancer+Dual-Targeting+and+Dual-Modality+Imaging+with+Functionalized+Quantum+Dots&rft.jtitle=The+Journal+of+nuclear+medicine+%281978%29&rft.au=Hu%2C+Kongzhen&rft.au=Wang%2C+Hongliang&rft.au=Tang%2C+Ganghua&rft.au=Huang%2C+Tingting&rft.date=2015-08-01&rft.issn=0161-5505&rft.volume=56&rft.issue=8&rft.spage=1278&rft.epage=1278&rft_id=info:doi/10.2967%2Fjnumed.115.158873&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0161-5505&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0161-5505&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0161-5505&client=summon |